9 Analysts Have This to Say About Viridian Therapeutics
Portfolio Pulse from Benzinga Insights
Nine analysts have given their ratings on Viridian Therapeutics (NASDAQ:VRDN) over the last quarter, with three being bullish, six somewhat bullish, and none being bearish or indifferent. The average price target is $44.0, indicating a potential upside from the current price of $19.58.
August 09, 2023 | 3:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Analysts are bullish on Viridian Therapeutics with an average price target of $44.0, indicating a potential upside.
The bullish ratings from analysts indicate a positive outlook for Viridian Therapeutics. The average price target of $44.0, which is significantly higher than the current price, suggests that analysts expect the stock price to rise in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100